Advances in the Treatment of Urological Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 9
Special Issue Editor
Interests: testicular cancer; prostate cancer; urothelial cancer; immunotherapy; de-escalation strategies; biomarkers; treatment resistance
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The progress made in the treatment of urological oncology has been extraordinary in recent years. New treatments, such as immunotherapies, hormonal and targeted therapies, antibody–drug conjugates, and radioligand therapies, have improved survival rates and quality of life for patients with various urological cancers. Additionally, precision medicine tools, utilising various platforms of molecular testing, have allowed for more personalised treatment plans. We are now entering an era of carefully crafting de-escalation and intensification approaches for metastatic disease, as well as intelligent early relapse detection and adjuvant therapy strategies. Our next-generation clinical trials are biomarker-guided, such as minimal residual disease detection surrogates that range from simple proteins (PSA in prostate cancer or PD-L1 expression in renal cancer) to microRNAs (miRNA-371 in testicular cancer) or ctDNA detection (urothelial cancer), or even radiomics (PSMA and other metabolic imaging in prostate cancer). This Special Issue invites the submission of papers focused on various therapies (e.g., chemotherapy, hormone therapy, immunotherapy, targeted therapy, radioligand therapies, novel therapeutics) in urological cancers.
Dr. Anna Patrikidou
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- urological oncology
- chemotherapy
- hormone therapy
- immunotherapy
- targeted therapy
- radioligand therapy
- antibody-drug conjugates
- novel therapeutics
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
